EUVIMED · CrossrefZeitschrift
Pulmonary Pharmacology & Therapeutics
ISSN 1094-5539 · Elsevier BV
Neueste Artikel
First-in-human safety and pharmacokinetic evaluation of seralutinib, an investigational inhaled tyrosine-protein kinase inhibitor for pulmonary hypertension
Tectochrysin alleviates idiopathic pulmonary fibrosis via inhibiting PI3K/AKT/mTOR signaling pathway by targeting PI3K p85
Experimental modeling of pulmonary fibrosis and combined emphysema in mice using repeated doses of bleomycin and cigarette smoke extract
A retrospective review of concurrent versus sequential administration of intrapleural tissue plasminogen activator and dornase alfa for empyemas
Real-life impact of genotype and severity of lung disease on efficacy of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis
Bispecific domain antibody attenuates airway hyperresponsiveness and pulmonary inflammation in ovalbumin-lipopolysaccharide induced asthma model by inhibiting IL-23 and TNF-α
The efficacy and safety of inhaled antibiotics for pneumonia: A systematic review and meta-analysis
Suboptimal peak inspiratory flow rate in dry-powder inhaler users for chronic obstructive pulmonary disease in Korea
Evaluating the pharmacokinetics of beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide delivered via pressurised metered-dose inhaler using a low global warming potential propellant
Ferroptosis mediates airway epithelial E-cadherin dysfunction in LPS-induced acute lung injury
Knockdown of HDAC10 inhibits POLE2-mediated DNA damage repair in NSCLC cells by increasing SP1 acetylation levels
m6A-modified miR-143-3p inhibits epithelial mesenchymal transition in bronchial epithelial cells and extracellular matrix production in lung fibroblasts by targeting Smad3
The impact of nintedanib and pirfenidone on lung function and survival in patients with idiopathic pulmonary fibrosis in real-life setting
Tyvaso DPI: Drug-device characteristics and patient clinical considerations
Anti-fibrotic effects of nintedanib on lung fibroblasts derived from patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)
Impact of statin treatment and exposure on the risk of chronic allograft dysfunction in Chinese lung transplant recipients
Weight loss in nintedanib-treated patients with idiopathic pulmonary fibrosis
Treatment of respiratory viral infections through inhalation therapeutics: Challenges and opportunities
Comparative clinical pharmacology of mometasone furoate, fluticasone propionate and fluticasone furoate
Effects of inhaled JAK inhibitor GDC-4379 on exhaled nitric oxide and peripheral biomarkers of inflammation
The immunomodulatory effects of macrolide antibiotics in respiratory disease
HDAC8-inhibitor PCI-34051-induced exosomes inhibit human bronchial smooth muscle cell proliferation via miR-381-3p mediated TGFB3
Inhaled bronchodilators use and clinical course of adult inpatients with Covid-19 pneumonia in Spain: A retrospective cohort study
The anti-inflammatory effects of cannabidiol and cannabigerol alone, and in combination
Corrigendum to “Myricetin inhibits TNF-α-induced inflammation in A549 cells via the SIRT1/NF-κB pathway” [Pulm. Pharmacol. Therapeut. 65 (2020) 102000]
Genetic variants in MIR2113 and MIR129-LEP are associated with the susceptibility of COPD in the Chinese Han population
Tetrahydropalmatine protects against acute lung injury induced by limb ischemia/reperfusion through restoring PI3K/AKT/mTOR-mediated autophagy in rats
Investigating the effect of TRPV4 inhibition on pulmonary-vascular barrier permeability following segmental endotoxin challenge
JMV5656, a short synthetic derivative of TLQP-21, alleviates acid-induced lung injury and fibrosis in mice
Bergenin-activated SIRT1 inhibits TNF-α-induced proinflammatory response by blocking the NF-κB signaling pathway
EUVIMED